Evidence map›Paper›PMID 38039509›Full record

ArticleBlood advances2024

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.

Edward Poynton, Emily Chernucha, James Day, Catherine Prodger, David Hopkins, Pallav Rakesh, Tess O'Neill, Nisha Thakrar, Ayse Akarca, Esraa Jamal and 14 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 1 country.

Edward PoyntonCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Emily ChernuchaNottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
James DayDepartment of Clinical Haematology, University College London Hospital, London, United Kingdom.
Catherine ProdgerOxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, United Kingdom.
David HopkinsBeatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Pallav RakeshCentre for Clinical Haematology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Tess O'NeillDepartment of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
Nisha ThakrarDepartment of Clinical Haematology, University College London Hospital, London, United Kingdom.
Ayse AkarcaDepartment of Histopathology, University College London Hospital, London, United Kingdom.
Esraa JamalCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Ayesha AliCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
Amy A KirkwoodCancer Research UK and UCL Cancer Trial Centre, UCL Cancer Institute, University College London, London, United Kingdom.
Sabine PomplunDepartment of Histopathology, University College London Hospital, London, United Kingdom.
Teresa MarafiotiDepartment of Histopathology, University College London Hospital, London, United Kingdom.
Maria CalaminiciCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Paul GreavesDepartment of Haematology, Barking Havering and Redbridge University Hospital NHS Trust, Romford, United Kingdom.
Sridhar ChagantiCentre for Clinical Haematology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Pam McKayBeatson West of Scotland Cancer Centre, Glasgow, United Kingdom.ORCID 0000-0002-3959-9730
Jeffery SmithClatterbridge Cancer Centre, Liverpool University Hospitals, Liverpool, United Kingdom.
Toby A EyreOxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, United Kingdom.ORCID 0000-0002-6631-9749
Nicolas Martinez-CalleNottingham University Hospitals NHS Trust, Nottingham, United Kingdom.ORCID 0000-0002-5184-9464
Kate CwynarskiDepartment of Clinical Haematology, University College London Hospital, London, United Kingdom.
Christopher P FoxSchool of Medicine, University of Nottingham, Nottingham, United Kingdom.
Jessica OkosunCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-6021-5044
University College Hospital · GBQueen Mary University of London · GBBeatson West of Scotland Cancer Centre · GBChurchill Hospital · GBNottingham University Hospitals NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBBarking, Havering And Redbridge University Hospitals NHS Trust · GBCancer Research UK · GBCancer Research UK Clinical Trials Unit · GBClatterbridge Cancer Centre NHS Foundation Trust · GBSt Bartholomew's Hospital · GBUniversity of Nottingham · GB

Funding

Cancer Research UK 25354
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, Large B-Cell, DiffuseGene RearrangementHumansProto-Oncogene Proteins c-bcl-2United KingdomBCL2 protein, humanProto-Oncogene Proteins c-bcl-2

Identifiers

PMID38039509
PMCPMC10985804
OpenAlexW4389231538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.